MRS. CHRISTINA ALLEN CNP
Prescription History 1922407618
Nurse Practitioner - Women's Health in Boston, MA

NPI Status: Active since August 19, 2014

Contact Information

55 FRUIT ST # 4
BOSTON, MA
ZIP 02114
Phone: (617) 724-6850

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MRS. CHRISTINA ALLEN CNP, an active Women's Health specialist practicing in Boston, MA. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 800 documented patient claims. Among these therapy options, the most frequently utilized medication is Gemtesa, which accounts for 192 claims alone.


Estradiol

Generic Formulation: EstradiolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 176
30-Day Fills 458.1
Days Supply 13,686
MA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills75.6
Peer Average Days Supply2,251
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 433.3% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,785.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$89.69

State Avg Cost Per Claim

$110.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estring

Generic Formulation: EstradiolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 50
30-Day Fills 148.2
Days Supply 4,446
MA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills66.9
Peer Average Days Supply2,005
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 127.3% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,612.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$532.25

State Avg Cost Per Claim

$522.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Gemtesa

Generic Formulation: VibegronSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 192
30-Day Fills 281.7
Days Supply 8,435
MA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills60.9
Peer Average Days Supply1,773
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 346.5% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $140,626.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$732.43

State Avg Cost Per Claim

$643.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat overactive bladder. Overactive bladder is a problem with how your bladder stores urine that causes a sudden urge to urinate. The urge may be hard to control, and overactive bladder symptoms may include frequent urination, strong sudden urges to urinate, or involuntary loss of urine (incontinence). Vibegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder.

Methenamine Hippurate

Generic Formulation: Methenamine HippurateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 94
30-Day Fills 149.0
Days Supply 4,470
MA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills52.9
Peer Average Days Supply1,485
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 154.1% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,557.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.40

State Avg Cost Per Claim

$89.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Methenamine is used to prevent or control returning urinary tract infections caused by certain bacteria. It is not used to treat an active infection. Antibiotics must be used first to treat and cure the infection. Methenamine is a drug that stops the growth of bacteria in urine. This medication also contains an ingredient that helps to make the urine acidic. When the urine is acidic, methenamine turns into formaldehyde to kill the bacteria. This drug is effective only against bacterial infections in the urinary tract. It will not work for other types of bacterial infections (such as in the blood) or for viral infections (such as the common cold or flu). Unnecessary use or misuse of any antibacterial drug can lead to its decreased effectiveness.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 149
30-Day Fills 183.0
Days Supply 5,490
MA State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills74.8
Peer Average Days Supply2,074
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 170.9% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $85,250.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$572.15

State Avg Cost Per Claim

$561.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Nitrofurantoin Mono-Macro

Generic Formulation: Nitrofurantoin Monohyd/M-CrystSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 75
MA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills24.7
Peer Average Days Supply212
Conservative Utilization

This provider writes prescriptions for this formulation 39.1% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $188.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.45

State Avg Cost Per Claim

$20.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antibiotic used to treat bladder infections (acute cystitis). It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 25
30-Day Fills 50.5
Days Supply 1,515
MA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills30.8
Peer Average Days Supply898
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 47.1% more claims than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,400.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$456.00

State Avg Cost Per Claim

$389.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Trospium Chloride

Generic Formulation: Trospium ChlorideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 23
30-Day Fills 49.0
Days Supply 1,470
MA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills52.0
Peer Average Days Supply1,520
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,037.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$88.59

State Avg Cost Per Claim

$87.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

Trospium Chloride Er

Generic Formulation: Trospium ChlorideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 31
30-Day Fills 60.0
Days Supply 1,800
MA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills51.2
Peer Average Days Supply1,507
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,938.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$223.83

State Avg Cost Per Claim

$200.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

Yuvafem

Generic Formulation: EstradiolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 46
30-Day Fills 118.2
Days Supply 3,542
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills58.1
Peer Average Days Supply1,729
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 91.7% higher than the standard regional baseline profile for MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,073.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$175.52

State Avg Cost Per Claim

$184.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MRS. CHRISTINA ALLEN CNP provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Women's Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.